|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirano T: IL-6 in inflammation,
autoimmunity and cancer. Int Immunol. 33:127–148. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Michalaki V, Syrigos K, Charles P and
Waxman J: Serum levels of IL-6 and TNF-alpha correlate with
clinicopathological features and patient survival in patients with
prostate cancer. Br J Cancer. 90:2312–2316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Browning L, Patel MR, Horvath EB, Tawara K
and Jorcyk CL: IL-6 and ovarian cancer: Inflammatory cytokines in
promotion of metastasis. Cancer Manag Res. 10:6685–6693. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Dijk E, van den Bosch T, Lenos KJ, El
Makrini K, Nijman LE, van Essen HFB, Lansu N, Boekhout M, Hageman
J, Fitzgerald RC, et al: Chromosomal copy number heterogeneity
predicts survival rates across cancers. Nat Commun. 12:31882021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu L, McBride KM and Reich NC: STAT-3
nuclear import is independent of tyrosine phosphorylation and
mediated by importin-alpha3. Proc Natl Acad Sci USA. 102:8150–8155.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamran MZ, Patil P and Gude RP: Role of
STAT-3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Horvath CM: The Jak-STAT pathway
stimulated by interleukin 6. Sci STKE. 23:tr92004.PubMed/NCBI
|
|
10
|
Don-Doncow N, Marginean F, Coleman I,
Nelson PS, Ehrnstrom R, Krzyzanowska A, Morrissey C, Hellsten R and
Bjartell A: Expression of STAT-3 in prostate cancer metastases. Eur
Urol. 71:313–316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ,
Zhou SL, Zhou YM, Xiao YS, Sun QM, Ding ZB and Fan J:
Macrophage-secreted IL-8 induces epithelial-mesenchymal transition
in hepatocellular carcinoma cells by activating the
JAK2/STAT-3/Snail pathway. Int J Oncol. 46:587–596. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song W, Mazzieri R, Yang T and Gobe GC:
Translational significance for tumor metastasis of tumor-associated
macrophages and epithelial-mesenchymal transition. Front Immunol.
8:11062017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun M, Liu C, Nadiminty N, Lou W, Zhu Y,
Yang J, Evans CP, Zhou Q and Gao AC: Inhibition of STAT-3
activation by sanguinarine suppresses prostate cancer cell growth
and invasion. Prostate. 72:82–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong H, Hong J, Du W, Lin YW, Ren LL,
Wang YC, Su WY, Wang JL, Cui Y, Wang ZH and Fang JY: Roles of
STAT-3 and ZEB1 proteins in E-cadherin down-regulation and human
colorectal cancer epithelial-mesenchymal transition. J Biol Chem.
287:5819–5832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masjedi A, Hashemi V, Hojjat-Farsangi M,
Ghalamfarsa G, Azizi G, Yousefi M and Jadidi-Niaragh F: The
significant role of interleukin-6 and its signaling pathway in the
immunopathogenesis and treatment of breast cancer. Biomed
Pharmacother. 108:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim NH, Kim SK, Kim DS, Zhang D, Park JA,
Yi H, Kim JS and Shin HC: Anti-proliferative action of
IL-6R-targeted antibody tocilizumab for non-small cell lung cancer
cells. Oncol Lett. 9:2283–2288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alraouji NN and Aboussekhra A: Tocilizumab
inhibits IL-8 and the proangiogenic potential of triple negative
breast cancer cells. Mol Carcinog. 60:51–59. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siersbaek R, Scabia V, Nagarajan S,
Chernukhin I, Papachristou EK, Broome R, Johnston SJ, Joosten SEP,
Green AR, Kumar S, et al: IL6/STAT-3 signaling hijacks estrogen
receptor alpha enhancers to drive breast cancer metastasis. Cancer
Cell. 38:412–423.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small-molecule inhibitor of STAT-3 activation
and dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Du J, Zhao Q, Liu K, Li Z, Fu F, Zhang K,
Zhang H, Zheng M, Zhao Y and Zhang S: FGFR2/STAT-3 signaling
pathway involves in the development of MMTV-related spontaneous
breast cancer in TA2 mice. Front Oncol. 10:6522020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo Y, Lu Y, Long B, Lin Y, Yang Y, Xu Y,
Zhang X and Zhang J: Blocking DNA damage repair may be involved in
stattic (STAT-3 Inhibitor)-induced FLT3-ITD AML cell apoptosis.
Front Cell Dev Biol. 16:6370642021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moniri MR, Young A, Reinheimer K, Rayat J,
Dai LJ and Warnock GL: Dynamic assessment of cell viability,
proliferation and migration using real time cell analyzer system
(RTCA). Cytotechnology. 67:379–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarkar PL, Lee W, Williams ED, Lubik AA,
Stylianou N, Shokoohmand A, Lehman ML, Hollier BG, Gunter JH and
Nelson CC: Insulin enhances migration and invasion in prostate
cancer cells by up-regulation of FOXC2. Front Endocrinol
(Lausanne). 10:4812019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pfaffl MW: Relative quantification.
Real-time PCR. 63:63–82. 2006.
|
|
26
|
Alraouji NN, Al-Mohanna FH, Ghebeh H,
Arafah M, Almeer R, Al-Tweigeri T and Aboussekhra A: Tocilizumab
potentiates cisplatin cytotoxicity and targets cancer stem cells in
triple–negative breast cancer. Mol Carcinog. 59:1041–1051. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou S, Tong Q, Liu B, Huang W, Tian Y and
Fu X: Targeting STAT-3 in cancer immunotherapy. Mol Cancer.
19:1452020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hapach LA, Mosier JA, Wang W and
Reinhart-King CA: Engineered models to parse apart the metastatic
cascade. NPJ Precis Oncol. 3:202019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee H, Jeong AJ and Ye SK: Highlighted
STAT-3 as a potential drug target for cancer therapy. BMB Rep.
52:415–423. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zarif JC, Taichman RS and Pienta KJ: TAM
macrophages promote growth and metastasis within the cancer
ecosystem. Oncoimmunology. 3:e9417342014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baghban R, Roshangar L, Jahanban-Esfahlan
R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T and
Zare P: Tumor microenvironment complexity and therapeutic
implications at a glance. Cell Commun Signal. 18:592020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bakouny Z and Choueiri TK: IL-8 and cancer
prognosis on immunotherapy. Nat Med. 26:650–651. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT-3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Herrmann A, Lahtz C, Nagao T, Song JY,
Chan WC, Lee H, Yue C, Look T, Mülfarth R, Li W, et al: CTLA4
promotes Tyk2-STAT-3-dependent B-cell oncogenicity. Cancer Res.
77:5118–5128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bu LL, Yu GT, Wu L, Mao L, Deng WW, Liu
JF, Kulkarni AB, Zhang WF, Zhang L and Sun JZ: STAT-3 induces
immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J Dent Res.
96:1027–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S
and Jian Z: IL-6/STAT-3 pathway intermediates M1/M2 macrophage
polarization during the development of hepatocellular carcinoma. J
Cell Biochem. 119:9419–9432. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arneth B: Tumor microenvironment. Medicina
(Kaunas). 56:152019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kong D, Zhou H, Neelakantan D, Hughes CJ,
Hsu JY, Srinivasan RR, Lewis MT and Ford HL: VEGF-C mediates tumor
growth and metastasis through promoting EMT-epithelial breast
cancer cell crosstalk. Oncogene. 40:964–979. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ham IH, Oh HJ, Jin H, Bae CA, Jeon SM,
Choi KS, Son SY, Han SU, Brekken RA, Lee D and Hur H: Targeting
interleukin-6 as a strategy to overcome stroma-induced resistance
to chemotherapy in gastric cancer. Mol Cancer. 18:682019.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bie Y, Ge W, Yang Z, Cheng X, Zhao Z, Li
S, Wang W, Wang Y, Zhao X, Yin Z and Li Y: The crucial role of
CXCL8 and its receptors in colorectal liver metastasis. Dis
Markers. 2019:80234602019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Haque S and Morris JC: Transforming growth
factor-β: A therapeutic target for cancer. Hum Vaccin Immunother.
13:1741–1750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: Emt: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Green MM, Hiley CT, Shanks JH, Bottomley
IC, West CM, Cowan RA and Stratford IJ: Expression of vascular
endothelial growth factor (VEGF) in locally invasive prostate
cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol
Biol Phys. 67:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen J, De S, Brainard J and Byzova TV:
Metastatic properties of prostate cancer cells are controlled by
VEGF. Cell Commun Adhes. 11:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Plate K: From angiogenesis to
lymphangiogenesis. Nat Med. 7:151–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roberts E, Cossigny DA and Quan GM: The
role of vascular endothelial growth factor in metastatic prostate
cancer to the skeleton. Prostate Cancer. 2013:4183402013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin W, Wan X, Sun A, Zhou M, Chen X, Li Y,
Wang Z, Huang H, Li H, Chen X, et al: RUNX1/EGFR pathway
contributes to STAT-3 activation and tumor growth caused by
hyperactivated mTORC1. Mol Ther Oncolytics. 23:387–401. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Malik A, Pal R and Gupta SK:
Interdependence of JAK-STAT and MAPK signaling pathways during
EGF-mediated HTR-8/SVneo cell invasion. PLoS One. 12:e01782692017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Haverty AA, Harmey JH, Redmond HP and
Bouchier-Hayes DJ: Interleukin-6 upregulates GP96 expression in
breast cancer. J Surg Res. 69:145–149. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zeng J, Tang ZH, Liu S and Guo SS:
Clinicopathological significance of overexpression of interleukin-6
in colorectal cancer. World J Gastroenterol. 23:1780–1786. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Taher MY, Davies DM and Maher J: The role
of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc
Trans. 46:1449–1462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nguyen DP, Li J and Tewari AK:
Inflammation and prostate cancer: The role of interleukin 6 (IL-6).
BJU Int. 113:986–992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jin W: Role of JAK/STAT-3 signaling in the
regulation of metastasis, the transition of cancer stem cells, and
chemoresistance of cancer by epithelial-mesenchymal transition.
Cells. 9:2172020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huang SP, Wu MS, Shun CT, Wang HP, Lin MT,
Kuo ML and Lin JT: Interleukin-6 increases vascular endothelial
growth factor and angiogenesis in gastric carcinoma. J Biomed Sci.
11:517–527. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhong B, Shi D, Wu F, Wang S, Hu H, Cheng
C, Qing X, Huang X, Luo X, Zhang Z and Shao Z: Dynasore suppresses
cell proliferation, migration, and invasion and enhances the
antitumor capacity of cisplatin via STAT-3 pathway in osteosarcoma.
Cell Death Dis. 10:6872019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wu P, Wu D, Zhao L, Huang L, Shen G, Huang
J and Chai Y: Prognostic role of STAT-3 in solid tumors: a
systematic review and meta-analysis. Oncotarget. 7:19863–19883.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pan Y, Zhou F, Zhang R and Claret FX:
STAT-3 inhibitor stattic exhibits potent antitumor activity and
induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.
PLoS One. 8:e545652013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rebe C, Vegran F, Berger H and
Ghiringhelli F: STAT-3 activation: A key factor in tumor
immunoescape. JAKSTAT. 2:e230102013.PubMed/NCBI
|
|
62
|
Suarez AA, Van Renne N, Baumert TF and
Lupberger J: Viral manipulation of STAT-3: Evade, exploit, and
injure. PLoS Pathog. 14:e10068392018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wendt MK, Balanis N, Carlin CR and
Schiemann WP: STAT-3 and epithelial-mesenchymal transitions in
carcinomas. JAKSTAT. 3:e289752014.PubMed/NCBI
|
|
64
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Leidgens V, Proske J, Rauer L, Moeckel S,
Renner K, Bogdahn U, Riemenschneider MJ, Proescholdt M,
Vollmann-Zwerenz A, Hau P and Seliger C: Stattic and metformin
inhibit brain tumor initiating cells by reducing
STAT-3-phosphorylation. Oncotarget. 8:8250–8263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liang R, Chen X, Chen L, Wan F, Chen K,
Sun Y and Zhu X: STAT-3 signaling in ovarian cancer: A potential
therapeutic target. J Cancer. 11:837–848. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Thulin MH, Määttä J, Linder A, Sterbova S,
Ohlsson C, Damber JE, Widmark A and Persson E: Inhibition of STAT-3
prevents bone metastatic progression of prostate cancer in vivo.
Prostate. 81:452–462. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yu D, Qi S, Guan X, Yu W, Yu X, Cai M, Li
Q, Wang W, Zhang W and Qin JJ: Inhibition of STAT-3 signaling
pathway by terphenyllin suppresses growth and metastasis of gastric
cancer. Front Pharmacol. 13:8703672022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Canesin G, Maggio V, Palominos M, Stiehm
A, Contreras HR, Castellon EA, Morote J, Paciucci R, Maitland NJ,
Bjartell A and Hellsten R: STAT-3 inhibition with galiellalactone
effectively targets the prostate cancer stem-like cell population.
Sci Rep. 10:139582020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xu X, Dang Z, Zhang J, Feng Y and Wei Z:
The miRNA, miR-125b, inhibited invasion and metastasis of
gastric-cancer cells by triggering the STAT-3 signaling pathway.
Cancer Manag Res. 12:8569–8580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Saad F and Hotte SJ: Guidelines for the
management of castrate-resistant prostate cancer. Can Urol Assoc J.
4:380–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Thaper D, Vahid S, Kaur R, Kumar S,
Nouruzi S, Bishop JL, Johansson M and Zoubeidi A: Galiellalactone
inhibits the STAT-3/AR signaling axis and suppresses
enzalutamide-resistant prostate cancer. Sci Rep. 8:173072018.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hua Y, Azeem W, Shen Y, Zhang S, Olsen JR,
Oyan AM, Ke X, Zhang W and Kalland KH: Dual androgen receptor (AR)
and STAT-3 inhibition by a compound targeting the AR amino-terminal
domain. Pharmacol Res Perspect. 6:e004372018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu C, Zhu Y, Lou W, Cui Y, Evans CP and
Gao AC: Inhibition of constitutively active STAT-3 reverses
enzalutamide resistance in LNCaP derivative prostate cancer cells.
Prostate. 74:201–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang Y, Guo W, Li Z, Wu Y, Jing C, Ren Y,
Zhao M, Kong L, Zhang C, Dong J, et al: Role of the EZH2/miR-200
axis in STAT-3-mediated OSCC invasion. Int J Oncol. 52:1149–1164.
2018.PubMed/NCBI
|
